Gen2 Neuroscience

Gen2 Neuroscience is a private, pre-clinical stage biotech targeting neurodegenerative diseases, particularly tauopathies like Alzheimer's disease. Its core strategy involves using human stem cell-derived models to understand disease propagation and to develop highly selective antibodies that block the uptake of extracellular, toxic tau while sparing normal tau. The company's lead program, Gen2B, aims to slow disease progression, and it has secured backing from the specialized Dementia Discovery Fund. Led by a small, experienced team, Gen2 is positioned in a high-need but challenging therapeutic area.

Utilizes state-of-the-art human stem cell models of neurodegenerative disease to understand disease spread mechanisms and identify extracellular, pathogenic forms of the tau protein for targeted drug discovery.

Gen2 operates in the competitive tauopathy therapeutic space, facing rivals from large pharma (e.g., Biogen, Roche, Eli Lilly) and biotechs developing various anti-tau antibodies, small molecules, and other modalities. Its differentiation lies in its stem cell platform for target identification and its focus on antibodies designed to selectively bind pathogenic tau species.